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Abstract
Background: Administrative data is often used to identify patients with chronic obstructive pulmonary disease
(COPD), yet the validity of this approach is unclear. We sought to develop a predictive model utilizing
administrative data to accurately identify patients with COPD.
Methods: Sequential logistic regression models were constructed using 9573 patients with postbronchodilator
spirometry at two Veterans Affairs medical centers (2003-2007). COPD was defined as: 1) FEV1/FVC <0.70, and 2)
FEV1/FVC < lower limits of normal. Model inputs included age, outpatient or inpatient COPD-related ICD-9 codes,
and the number of metered does inhalers (MDI) prescribed over the one year prior to and one year post
spirometry. Model performance was assessed using standard criteria.
Results: 4564 of 9573 patients (47.7%) had an FEV1/FVC < 0.70. The presence of ≥1 outpatient COPD visit had a
sensitivity of 76% and specificity of 67%; the AUC was 0.75 (95% CI 0.74-0.76). Adding the use of albuterol MDI
increased the AUC of this model to 0.76 (95% CI 0.75-0.77) while the addition of ipratropium bromide MDI
increased the AUC to 0.77 (95% CI 0.76-0.78). The best performing model included: ≥6 albuterol MDI, ≥3
ipratropium MDI, ≥1 outpatient ICD-9 code, ≥1 inpatient ICD-9 code, and age, achieving an AUC of 0.79 (95% CI
0.78-0.80).
Conclusion: Commonly used definitions of COPD in observational studies misclassify the majority of patients as
having COPD. Using multiple diagnostic codes in combination with pharmacy data improves the ability to
accurately identify patients with COPD.
Background
Chronic obstructive pulmonary disease (COPD) is a sig-
nificant cause of morbidity and mortality in the United
States and throughout the world [1]. COPD consumes
substantial healthcare resources and is among the most
expensive medical conditions in the United States [2,3].
Due to the magnitude of the public health and eco-
nomic burden of COPD, investigators are actively
researching all aspects of the genetics, biology, patho-
physiology, epidemiology, pharmacotherapy, and health-
care delivery of COPD [4].
The Global Initiative for Chronic Obstructive Lung
Disease (GOLD), a partnership between the World
Health Organization (WHO) and the National Heart,
Lung and Blood Institute, define COPD as the presence
of postbronchodilator airflow limitation documented as
a fixed ratio FEV1/FVC < 0.7 on spirometry [5]. How-
ever, there continues to be disagreement among profes-
sional societies as to the optimal physiologic criteria to
define COPD [6]. While investigators have performed
spirometry in population samples quantify the preva-
lence of COPD throughout the world, such studies are
expensive and time consuming to conduct [7-9]. The
challenges of obtaining spirometry limit the ability of
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investigate differences in COPD care practice across
broad geographic regions within the United States.
Many investigators combat these issues by utilizing
administrative databases to provide information about
the epidemiology of and the care delivered to patients
with COPD [10]. The literature is replete with exam-
ples of the use of COPD International Classification of
Diseases, 9th Revision, Clinical Modification (ICD-9)
diagnosis codes to identify COPD cases [10-15] and
COPD exacerbations [16-18]. Despite the common use
of ICD-9 codes to define COPD in the literature,
there is limited data on the validity of such codes
[16,19-21]. Prior studies examining the validity of
ICD-9 codes utilize medical record review[20,21] or
physician diagnosis[16] as the gold standard for
COPD. There is limited data characterizing the perfor-
mance of ICD-9 codes when spirometry is used as the
gold standard [22].
We sought to develop a predictive model that would
best identify COPD patients using administrative data
when spirometry was the gold standard. We focused on
determining the performance of outpatient and inpatient
ICD-9 codes, but evaluated the ability of additional
information, such as age, pharmacy records, and smok-
ing status, to improve the performance of ICD-9 codes
in identifying patients with COPD.
Methods
Study design
We conducted a secondary analysis of data collected as
part of an observational study of medication adherence
among patients with COPD.
Setting and participants
We utilized the Department of Veterans Affairs (VA)
inpatient and outpatient databases to screen all patients
receiving any inpatient or outpatient care at two VA
medical centers in the Pacific Northwest between
January, 2003 and December, 2007. We defined the
index date when patients entered the sample as the date
on which the first pulmonary function test (PFT) includ-
ing spirometry was performed. We excluded all patients
who did not receive postbronchodilator spirometry from
our analysis. We also excluded patients with a past or
current diagnosis of lung cancer and patients with a
BMI < 15 or ≥55 as these patients may have evidence of
airflow obstruction for reasons other COPD.
Data Collection and definitions
We collected demographic data, pharmacy records and
the primary ICD-9 code for all outpatient and inpatient
visits during the exact calendar date one year pre- and
one year post the index date utilizing the VA computer-
ized medical record system.
Patients with any of the following primary ICD-9
codes were considered to have a COPD-related visit:
491.xx - chronic bronchitis, 492.xx - emphysema, 493.2 -
chronic obstructive asthma, 496.xx - chronic airway
obstruction, not elsewhere classified. We did not include
490 - Bronchitis, not specified as acute or chronic in our
administrative definition of COPD because the defini-
tion itself lacks specificity which increases the concern
about misclassification [23,24]. Outpatient primary and
secondary ICD-9 codes were those recorded during a
patient encounter in any outpatient clinic while inpati-
ent primary ICD-9 codes were those recorded during an
admission to the hospital. ICD-9 codes generated during
visits to the pulmonary function laboratory were not
considered in this analysis. Although secondary ICD-9
codes were considered for defining a COPD-related visit
these were uncommonly (<7% of visits) coded by provi-
ders. Comorbid conditions relevant to patients with
COPD were determined using ICD-9 codes for all pre-
vious outpatient visits in the one year period prior to
the index date. These included a diagnosis of lung
cancer (162.x, 163.x), acute coronary syndrome (410.xx,
411.xx), congestive heart failure (398.91,415.xx, 416.
xx,425.x, 428.x), diabetes (250.x), hypertension (401.xx-
405.xx), atrial fibrillation (427.xx), depression (311,
300.4, 296.2x, 296.3x), and schizophrenia (295.xx).
Smoking was assessed at the time of spirometry;
patients were classified as never/former or current based
upon self report. We determined the total number of
metered dose inhaler (MDI) canisters prescribed over
the two year period to each patient for both albuterol
and ipratropium bromide (categorized as: albuterol - 0,
1-5, 6+ MDI; ipratropium - 0, 1-2, 3+) using the Veter-
ans Integrated Service Network (VISN) data warehouse.
The VISN data warehouse contains the complete phar-
macy records for patients who filled prescriptions within
the VISN region. These data include the drug name,
class, prescription identification number, prescription fill
dates (primary and refills), number of allowable refills,
date of next allowable refill, amount dispensed, day sup-
ply, unit price of the medication and directions for use.
Nebulized medications were not included in the calcula-
tion of these totals. Tiotropium was not included in our
analysis as it was adopted slowly in the VA because of
formulary restriction.
COPD criterion standard
First, we categorized patients using the GOLD criterion:
postbronchodilator FEV1/FVC < 0.70 to define COPD.
Although experts are actively debating which COPD cri-
terion standard is optimal, GOLD is criticized for identi-
fying false positives among older patients [25,26]. The
second definition used a postbronchodilator FEV1/FVC
< lower limit of normal (LLN), where the LLN is
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defined by the referent equations of Hankinson, et al
[27]. At both centers, spirometry was performed in
accordance with the ATS guidelines for reproducibility
[28].
Statistical analysis
Bivariate comparisons utilized the t-test or Χ2 test as
appropriate for the distribution of the variable. We con-
sidered a p-value < 0.05 statistically significant.
Model development
We pre-specified an approach involving the sequential
addition of variables to a multiple logistic regression
model for each standard. We considered alternative
approaches to model development including classifica-
tion and regression tress (CART) and neural networks,
but neither of these approaches has been consistently
shown to outperform logistic regression for most classi-
fication problems in medicine [29-31]. We first assessed
a model containing a single variable representing the
presence/absence of ≥1 outpatient COPD-related ICD-9
code. We then increased the number of codes repre-
sented by the indicator variable to ≥3 codes. We then
evaluated the performance of ≥1 inpatient COPD-related
ICD-9 code. Next, we added pharmacy variables and age
to the prior models to characterize changes in the per-
formance of the model after such additions. Because
smoking status was assessed by interviewing the patient
at the time of spirometry, it is not considered an admin-
istrative variable. Nevertheless, this variable may be
available to investigators when identifying cohorts of
patients with COPD so we added it at the last stage of
model development.
We stratified all models by age ≥ 65 years by interact-
ing age (≥65 years) with all variables in each model.
This approach allowed separate coefficient estimates for
patients ≥ 65 and <65 years of age allowing one to apply
the model to Medicare and non-Medicare patients, but
provides one number for each estimate of model perfor-
mance (e.g AUC, Hosmer-Lemeshow, etc).
Model evaluation
Model performance was assessed by evaluating the sen-
sitivity and specificity of each model (cut point for the
predicted probability of COPD = 0.5), and the discrimi-
nation and calibration of each model. Discrimination
was determined by calculating the area under the recei-
ver operating characteristic curve (AUC or C-statistic).
Calibration was assessed using the Hosmer-Lemeshow
goodness-of-fit statistic. We calculated the Brier score
for each model as an alternative measure of accuracy
that incorporates features of discrimination and calibra-
tion as a single measure. The Brier score is calculated as
the mean squared error of the model and describes the
magnitude by which the predicted probability of COPD
generated by the model deviates from the true COPD
status of the patient. Because model performance rather
than parsimony was our primary concern, we did not
employ measures such as the Akaike information cri-
teria during the model building process [32].
For the best performing model containing only admin-
istrative variables we determined the sensitivity, specifi-
city, positive and negative predictive values for three cut
points (0.25, 0.5 and 0.75) in the model-based predicted
probability of COPD. These cut points illustrate the tra-
deoff in sensitivity and specificity of the model over the
range of predicted values. Patients with a model-based
probability of COPD greater than the cut point were
classified as having COPD. Because the prevalence of
COPD in our cohort was high, we also estimated the
positive and negative predictive values for the best per-
forming model using prevalence estimates closer to that
experienced in the general population (10-20%) [7,9,25].
Validation and sensitivity analysis
We utilized the bootstrap (2000 iterations) to internally
validate the best performing model. We selected this
previously described approach[33] instead of split sam-
ple internal validation because it provides an more accu-
rate, unbiased estimate of performance in external
cohorts. No external validation was performed.
Finally, we performed two sensitivity analyses to assess
the impact of our cohort definition on the results.
Because BMI is not captured in most administrative
data sources, we re-fit all models after including all
patients regardless of BMI. Since the specificity of ICD-
9 codes for COPD in younger patients may be low, we
also re-fit each model after excluding patients who were
< 40 years-old (n = 552).
All analyses were performed using Stata 10.0 (Stata-
corp, College Station, TX). The institutional review
boards for the University of Washington and the partici-
pating Veterans Affairs centers approved of the study.
Results
Bivariate analysis
We identified 12,205 patients referred for spirometry
during the study period. We excluded patients who had
a past or current history of lung cancer (n = 330), a
BMI < 15 or ≥55 (n = 68), or no assessment of broncho-
dilator response (n = 2234). After these exclusions, the
cohort contained 9573 (78.4%) patients with at least one
postbronchodilator assessment (Additional file 1).
Among patients assessed, 4564 (47.7%) had fixed airflow
obstruction (FEV1/FVC <0.70). Patient demographics,
comorbidities, and disease severity are shown in
Table 1. Compared to patients with airflow obstruction,
patients without airflow obstruction were younger, more
often female, and had greater prevalence of diabetes and
depression. Patients with obstruction were more likely
to be current smokers at the time of PFTs. Patients with
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fixed airflow obstruction had a lower FEV1 compared to
patients without obstruction (1.74 vs. 2.74 L, p < 0.001)
respectively. The most common degree of obstruction
among patients with obstruction was moderate (48%).
Patients with fixed airflow obstruction were also more
likely to be prescribed a greater number of MDIs for
both albuterol and iprotropium bromide than patients
without airflow obstruction.
Multivariable analysis
The performance characteristics of the series of models
we developed utilizing ICD-9 codes, pharmacy data, age,
and smoking status are presented for each reference
standard in Table 2. In general, ICD-9 codes by them-
selves exhibited a modest ability to classify a patient as
having airflow obstruction, regardless of the standard
(models 1-3), with outpatient codes providing better dis-
criminative ability than inpatient codes (model 1 vs.
model 4). Increasing the minimum necessary number of
outpatient visits with a primary ICD-9 code for COPD
to define airflow obstruction resulted in minimal impact
on the AUC beyond that provided by the presence of
one or more outpatient diagnostic codes (models 1-3).
However, specificity of the model improved when more
Table 1 Characteristics of cohort by presence of fixed airflow obstruction (GOLD/ATS/ERS standard)
Cohort (n = 9573)
No fixed obstruction Fixed obstruction p value
Characteristic* (FEV1/FVC > 0.70) (FEV1/FVC ≤ 0.70)
Subjects, n 5009 4564
Male, n (%) 4567 (91) 4435 (97) <0.001
Age, years 59 (14) 66 (11) <0.001
Body Mass Index, n (%) <0.001
15-18.5 29 (0.6) 135 (3.0)
18.5-25 714 (14) 1352 (30)
25-30 1664 (33) 1654 (36)
30-55 2602 (52) 1423 (31)
Comorbidities, n (%)
Hypertension 2667 (53) 2402 (53) 0.55
Diabetes 1174 (23) 792 (17) <0.001
Congestive heart failure 533 (11) 517 (11) 0.28
Myocardial infarction 101 (2) 113 (2.5) 0.13
Atrial fibrillation 504 (10) 496 (11) 0.20
Depression 1176 (23) 858 (19) <0.001
Schizophrenia 92 (1.8) 85 (1.9) 0.93
Smoking status, n (%) <0.001
Never/Former 3616 (72) 2633 (58)
Current 1393 (28) 1931 (42)
FEV1, L, mean (SD) 2.74 (0.81) 1.74 (0.74) <0.001
FEV1, % predicted, mean (SD) 80 (40) 54 (19) <0.001
Severity of airflow limitation (FEV1, % predicted), n (%)
GOLD I: Mild (≥80%) - 458 (10)
GOLD II: Moderate (50%-79%) - 2202 (48)
GOLD III: Severe (30%-49%) - 1362 (30)
GOLD IV: Very severe (<30%) - 541 (12)
Number of albuterol MDI, n (%)
0 2925 (58) 1789 (39)
1-5 1053 (21) 872 (19)
6+ 1031 (21) 1903 (42)
Number of ipratroprium MDI, n (%) <0.001
0 3936 (79) 2086 (46)
1-2 159 (3) 219 (5)
3+ 914 (18) 2259 (50)
*Numbers represent mean (SD) unless otherwise noted.
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; MDI, metered dose inhaler.
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outpatient ICD-9 codes were required to define obstruc-
tion. When added to a model with ≥1 outpatient ICD-9
code, MDI canister counts improved the discriminative
ability of the model (models 5, 6). Ipratropium bromide
(model 5) appeared to improve the AUC to a slightly
greater extent than albuterol (model 6) MDI canisters
(AUC 0.77 vs 0.76, respectively). The best performing
model utilizing only administrative data (model 8)
included the following variables: ≥6 albuterol MDI, ≥3
ipratropium MDI, ≥1 outpatient ICD-9 code, ≥1 inpati-
ent ICD-9 code, and age (model 8, AUC = 0.79, 95% CI
0.78-0.80, Table 2). The overall AUC was qualitatively
larger for GOLD standard than for the LLN standard,
although changes in the AUC were of similar magnitude
when variables were entered into the model. The addi-
tion of self reported smoking collected at the time of
PFT assessment minimally changed the AUCs and Brier
scores for both standards.
The best performing model incorporating only admin-
istrative data (model 8) for both standards was well
calibrated (Hosmer-Lemeshow statistic [GOLD p = 0.86;
LLN p = 0.50]). The Brier score was lowest for these
models as well (GOLD 0.187; LLN 0.187).
Coefficients for the best performing model utilizing
administrative data are shown in Table 3. These coeffi-
cients are presented for both airflow obstruction stan-
dards (GOLD, LLN) and are stratified by age ≥65 years.
Table 4 presents the sensitivity, specificity, positive and
negative predictive values for various cut points in the
model-based predicted probability of COPD generated
by model 8 for each diagnostic standard. Utilizing the
GOLD standard, setting the cut point in the model-
based predicted probability of COPD at 0.25 resulted in
a sensitivity (95% CI) of 91% (90-92%), specificity of
41% (39-42%), and positive and negative predictive
values of 58% (57-59%) and 83% (81-85%) respectively.
Setting the cut point higher in the model-based pre-
dicted probability of COPD resulted in greater positive
predictive values for both airflow obstruction standards.
Estimated PPV and NPV when the prevalence of COPD
Table 2 Sensitivity (sens), specificity (spec), discriminative performance (AUC) and calibration (Brier score, Hosmer-
Lemeshow [H-L] goodness of fit p-value) for models based on two years of administrative data
Standard for diagnosis of COPD
GOLD criterion LLN criterion
Model* (FEV1/FVC < 0.70) (FEV1/FVC < LLN)
AUC H-L AUC H-L
# Input variables Sens. (%)/Spec.
(%)
(95% CI) Brier p-value Sens.
(%)/Spec. (%)
(95% CI) Brier p-value
1 ≥1 outpatient ICD-9 code 76/67 0.75 (0.74-0.76) 0.198 79/62 0.71 (0.70-
0.72)
0.198
2 ≥2 outpatient ICD-9 code 70/73 0.75 (0.74-0.76) 0.199 73/69 0.72 (0.71-
0.73)
0.196
3 ≥3 outpatient ICD-9 codes 58/83 0.74 (0.73-0.75) 0.201 62/80 0.71 (0.70-
0.72)
0.195
4 ≥1 inpatient ICD-9 codes 55/67 0.62 (0.61-0.63) 0.235 6.5/99 0.57 (0.56-
0.58)
0.230
5 ≥1 outpatient ICD-9 codes
≥1 Ipratropium Bromide
MDI
76/67 0.77 (0.76-0.78) 0.192 53/83 0.75 (0.74-
0.76)
0.191
6 ≥1 outpatient ICD-9 codes
≥1 albuterol MDI 76/67 0.76 (0.75-0.77) 0.196 68/70 0.74 (0.73-
0.75)
0.195
7 ≥1 outpatient ICD-9 code
≥1 inpatient ICD-9 code
≥3 ipratropium bromide
MDI
≥6 albuterol MDI 68/76 0.78 (0.77-0.79) 0.190 60/79 0.76 (0.75-
0.77)
0.188
8 Model 7 and age 72/74 0.79 (0.78-0.80) 0.187 0.86 60/80 0.77 (0.76-
0.78)
0.187 0.50
9 Model 8 and smoking 73/74 0.79 (0.78-0.80) 0.185 0.65 60/81 0.77 (0.76-
0.78)
0.185 0.34
* All models are stratified by age ≥65 years. Input variables represent independent variables in the logistic regression equation for that particular model. All
variables modeled as dichotomous (present/absent) except for age (continuous).
AUC, area under the receiver operating characteristic curve; H-L, Hosmer-Lemeshow test; LLN, lower limit of normal; MDI, metered dose inhaler.
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is closer to population-based estimates (10 or 20%) are
presented in the Additional File 2.
Bootstrap internal validations of all models resulted in
insignificant changes in the AUC and are therefore not
reported. Inclusion of all patients regardless of BMI
resulted in no substantive changes in all models (data
not shown). There were no substantive changes in the
models’ performance when we limited the cohort to
patients over 40 years-old (Additional File 3).
Discussion
Utilizing over 9500 VA patients with postbronchodila-
tor spirometry we determined that ICD-9 codes have a
moderate to good ability to discriminate patients who
have fixed airflow obstruction from those who do not
with outpatient codes offering better performance than
inpatient codes. The addition of a patient’s age and
pharmacy data including the number of MDIs of albu-
terol and ipratropium bromide to outpatient and inpa-
tient ICD-9 codes improves the sensitivity and
specificity and the overall discriminative performance
of a model used to identify patients with airflow
obstruction. These variables showed similar perfor-
mance when utilizing GOLD criteria for airflow
obstruction compared to the LLN standard for airflow
obstruction.
Table 3 Logistic regression coefficients (beta) for GOLD and LLN diagnostic standard (model 8, table 2)
GOLD diagnostic standard
Age < 65 years Age ≥ 65 years
Variable Coefficient 95% CI p value Coefficient 95% CI p value
≥1 Outpatient ICD-9 visit 1.266 1.13, 1.40 <0.001 1.394 1.24, 1.55 <0.001
≥1 Inpatient ICD-9 visit 1.262 0.77, 1.75 <0.001 0.575 0.13, 1.02 0.01
≥3 Ipratropium MDI 0.708 0.56, 0.85 <0.001 0.603 0.44, 0.76 <0.001
≥6 Albuterol MDI 0.603 0.47, 0.74 <0.001 0.454 0.29, 0.62 <0.001
Age (per decade) 0.46 0.38, 0.55 <0.001 -0.05 -0.2, 0.1 0.39
Intercept -4.021 -4.49, -3.55 <0.001 -0.475 -1.33, 0.39 0.28
LLN diagnostic standard
Age < 65 years Age ≥ 65 years
Variable Coefficient 95% CI p value Coefficient 95% CI p value
≥1 Outpatient ICD-9 visit 1.260 1.12, 1.40 <0.001 1.501 1.33, 1.67 <0.001
≥1 Inpatient ICD-9 visit 1.163 0.73, 1.59 <0.001 0.475 0.22, 0.84 0.01
≥3 Ipratropium MDI 0.736 0.59, 0.88 <0.001 0.662 0.59, 0.82 <0.001
≥6 Albuterol MDI 0.606 0.47, 0.74 <0.001 0.509 0.35, 0.66 <0.001
Age (per decade) 0.16 0.07, 0.2 <0.001 -0.28 -0.4, -0.2 <0.001
Intercept -2.604 -3.03, -2.18 <0.001 0.319 -0.54, 1.18 0.47
MDI, metered dose inhaler; LLN, lower limit of normal.
Table 4 Sensitivity, specificity, PPV, and NPV for various predicted probabilities of COPD from logistic model 8 by
diagnostic standard
GOLD diagnostic standard (model 8)
Model-based predicted probability of COPD (95% CI)
Performance characteristic (%) ≥0.25 ≥0.50 ≥0.75
Sensitivity 90.9 (90.0-91.7) 71.9 (70.6-73.2) 35.7 (34.3-37.1)
Specificity 40.5 (39.2-41.9) 73.5 (72.3-74.8 92.2 (91.4-92.9)
PPV 58.2 (57.0-59.3) 71.2 (69.9-72.5) 80.7 (78.9-82.4)
NPV 83.0 (81.3-84.5) 74.2 (72.9-75.4) 61.1 (60.0-62.2)
LLN diagnostic standard (model 8)
Model-based predicted probability of COPD (95% CI)
Performance characteristic (%) ≥0.25 ≥0.50 ≥0.75
Sensitivity 83.1 (81.9-84.4) 59.8 (58.2-61.4) 7.5 (6.6-8.4)
Specificity 55.9 (54.6-57.2) 79.6 (78.6-80.6) 98.8 (98.5-99.1)
PPV 54.1 (52.7-55.4) 64.6 (63.0-66.3) 80.1 (75.5-84.2)
NPV 84.2 (83.0-85.3) 76.0 (75.0-77.1) 63.1 (62.1-64.1)
LLN, lower limit of normal; PPV, positive predictive value; NPV, negative predictive value.
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The use of ICD-9 codes to identify cohorts of patient
with COPD using administrative data is common
[11-18]. Investigators and payers have utilized these
codes to describe the epidemiology of COPD
[12,14,15,17,24,34-36], to evaluate the effectiveness and
safety of treatments in COPD[11,13,18,37,38], and more
recently, as a means to assess the quality of care pro-
vided to patients with COPD [16]. In fact, the National
Committee for Quality Assurance (NCQA) and the
Agency for Health Research and Quality (AHRQ) both
advocate for use of quality measures relying on ICD-9
code-based COPD case-identification [39,40]. It is there-
fore surprising that the validity of both outpatient and
inpatient ICD-9 codes for identifying patients with
COPD has not been rigorously studied in large
populations.
Most prior efforts to establish the validity of ICD-9
codes for COPD utilize chart review or physician con-
sensus as the gold standard. One of the most widely
referenced studies, conducted by Rawson and colleagues,
utilized the 1987 Saskatchewan health care data files to
assess the validity of inpatient COPD ICD-9 codes com-
pared to both the patient’s inpatient medical chart and
provider service data [20]. Two hundred patient charts
were randomly selected from the 4613 hospitalized
patients with a primary ICD-9 code for COPD (n =
496). The charted discharge diagnosis from the patient’s
medical record showed exact agreement for 94.2% of
these patients. However, overall concordance between
physician documentation of COPD related care and hos-
pital discharge COPD-related ICD-9 codes (490-493,
496) was 68%. An analysis by Ginde and colleagues uti-
lized a similar approach to determine the positive pre-
dictive value for principle ICD-9 codes to identify acute
exacerbations of COPD in the emergency department
[16]. A random sample of 200 patients was taken from
all 644 patients with a code for COPD (491.2x, 492.8,
496) at two academic medical centers between 2005 and
2006. Chart review for these patients was used to estab-
lish the gold standard for COPD exacerbation which
was defined as: 1) the presence of a respiratory infection,
2) change in cough or 3) change in sputum with known
physician diagnosed COPD. The overall positive predic-
tive value for the presence of any of the specified codes
was 97%. The positive predictive value for a code of 496
alone was 60% (95% CI 32-84%).
Finally, a more recent study using claims in Ontario,
Canada examined the combination of ICD-9 outpatient
codes and ICD-10 inpatient codes to identify patients
with COPD cared for by community providers [19]. The
combination of one or more outpatient ICD-9 codes
(491.xx, 492.xx, 496.xx) or one or more inpatient ICD-
10 codes (J41, J43, J44) had a sensitivity of 85% and spe-
cificity of 78.4% among 113 patients with COPD and
329 patients without COPD. An expert panel reviewed
each patient’s medical record to determine the gold
standard for COPD. Spirometry was available in only
180 patients and details about its collection were not
reported in the study. The study was further limited by
employing ICD-10 codes which have yet to be univer-
sally adopted by many countries around the world.
While these studies outlined above suggest that ICD-9
codes can be used to accurately identify physician
defined COPD, none universally employed spirometry to
define the criterion standard for COPD. Physician diag-
nosed COPD may not be the optimal gold standard to
define COPD. A number of previous studies highlight
the difficulty physicians have in correctly indentifying
COPD in the absence of spirometry. In North America
only 20-30% of patients billed for a COPD-related visit
have had spirometry to confirm or refute the diagnosis
of COPD [12,41-43]. Up to 20% of physicians con-
fronted with a standardized patient in a COPD exacer-
bation fail to correctly identify COPD as the cause of
respiratory complaints [44]. These data raise concerns
about the validity of the COPD gold standard used in
prior studies examining the use of ICD-9 codes to iden-
tify patients.
The only study utilizing primarily spirometry to define
COPD compared discrimination between patients with
asthma versus patients with COPD. The accuracy of
ICD-9 codes demonstrated excellent performance (AUC
0.98) for the calculated ratio of total COPD ICD-9
codes to total respiratory ICD-9 codes to differentiate
patients with asthma from patients with COPD; how-
ever, this comparison cannot develop models to predict
patients with COPD as the comparator was patients
with asthma. Finally, unlike our study, which included
over 9500 patients, this study was limited by its inclu-
sion of only 151 patients with COPD [22].
Our study has several strengths. Our gold standard for
COPD used the most rigorous definition possible - fixed
airflow obstruction on spirometry and captures a large
number of patients who had clinical indication for spiro-
metry. This is contrast to many of the previous studies
highlighted above.
Our results also have important implications for clini-
cal investigators and health services and health policy
analysts. We present the coefficients for a model incor-
porating administrative variables that can be used to
accurately identify patients with COPD. This equation
can be used by investigators to calculate the predicted
probability of airflow obstruction within novel cohorts.
The sensitivity, specificity, positive and negative predic-
tive values for cut points in the model-based predicted
probability of airflow obstruction will allow an investiga-
tor to maximize sensitivity or specificity depending on
the needs of the study practice. For example, one might
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select a lower cut point (0.25) in the model-based pre-
dicted probability of airflow obstruction if utilizing this
model to screen a clinical database to identify candidates
for a COPD clinical trial. In this situation, maximizing
sensitivity would capture the majority of patients with
true COPD but at the cost of a large number of false
positives. Study staff could access the medical records of
these patients to eliminate people without airflow
obstruction on spirometry.
We recognize several limitations to our analysis. First,
we did not externally validate our model in alternative
cohorts of patients. Model performance will likely drop
when our model is applied to different patients as a
result of geographic and temporal changes, differences
in data definitions and case-mix. We assessed the opti-
mism in the estimated AUC for our model utilizing the
bootstrap which resulted in no appreciable change in
the AUC, but recognize that external validation is a
necessary step prior to widespread use [45]. Second, our
model was derived on US veterans that were mostly
older white men. This may limit the generalizability of
our models if applied outside of the VA. In addition, the
primary reason for collection of ICD-9 codes in VA
patients is not for billing purposes. Differences in coding
practice between the VA and other organizations cap-
turing ICD-9 codes primarily for billing purposes may
alter the performance of our models if applied outside
the VA. Third, some degree of ascertainment bias is
likely present, as we were unable to assess clinic visits
and hospital admissions to non-VA facilities. Fourth, we
collected ICD-9 codes from the one year pre- and one
year post the date of spirometry, a time interval that
may have reduced the sensitivity and specificity of the
codes for COPD. For example, a provider may provide a
COPD code on initial evaluation only to learn that
spirometry rules out the diagnosis of COPD. Neverthe-
less, we believe the time interval we used is appropriate
because it approximates how ICD-9 codes are screened
in observational research and provides a conservative
estimate of their performance.
Finally, we limited our cohort to patients referred for
spirometry who received a bronchodilator during their
test. This was done to ensure that we had a rigorous gold
standard by which we defined COPD, but may limit the
applicability of our model to only patients who are clini-
cally referred for spirometry. Given the high prevalence
of COPD in this population, and the VA more generally
[46], the positive predictive value of our model will
decrease if applied to a broader population. Several stu-
dies suggest that the prevalence of physiologically deter-
mined COPD is closer to 10-20%[7,9,25], which is
considerably lower than the 48% prevalence observed in
our sample. By limiting our analysis to only patients
referred to spirometry we provide a conservative estimate
of the models performance if applied to a general popula-
tion. Discriminating patients with COPD from those
without COPD among patients who are ill enough to be
referred to spirometry is likely a more difficult task than
discriminating COPD patients from those without COPD
among all patients in a general population. Nevertheless,
the estimates of the positive and negative predictive
values will change when applying our model to cohorts
with different COPD prevalence. Additional testing of
our model in broader populations should be done prior
to widespread use.
Conclusion
Administrative data are ubiquitous, are employed in all
aspects of healthcare, and are frequently being used to
understand the health and healthcare of patients with
COPD. Healthcare payers, policy makers, and investiga-
tors using administrative data to study COPD rely upon
valid assessment of disease status when conducting ana-
lyses. Currently used definitions of COPD in observa-
tional studies misclassify the majority of patients as
having COPD. We determined that ICD-9 codes in
combination with pharmacy data can accurately identify
patients with COPD. Further validation of our model is
required prior to its widespread application.
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